TetraLogic Pharmaceuticals EBIT

TetraLogic Pharmaceuticals (TLOG) currently reports a EBIT of $-49M as of September 2016. That compares with $-39M in the prior-year period — down 25.0% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore TetraLogic Pharmaceuticals's EBIT history and peer comparisons.

TetraLogic Pharmaceuticals's EBIT decreased from $-39M to $-49M — a 25.0% year-over-year decrease (period ending September 2016). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

TetraLogic Pharmaceuticals's EBIT of $-49M is lower than the Healthcare sector average of $22B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

TetraLogic Pharmaceuticals reported $-49M in EBIT as of September 2016. That compares with $-39M in the prior-year period — down 25.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-49M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for TetraLogic Pharmaceuticals, and consider following TLOG for alerts when major investors trade the stock.